Napo Pharmaceuticals, Inc.

Napo Participation in Call to Action to Prevent Deaths From Diarrheal Diseases in Children Under Five Years of Age

Published in AIDS Weekly, June 8th, 2009

Napo Pharmaceuticals, Inc. (“Napo”) is proud to announce that the Company is part of the Call to Action led by PATH, UNICEF, and WHO to raise the visibility of diarrheal disease and solutions to address it. The Call to Action includes the invitation to “invest in the research and development of new effective, appropriate and affordable prevention and treatment options for diarrheal disease.”

Napo's drug development efforts should come as welcome news for all those supporters of such a call to action and to those who suffer from the immense mortality and morbidity imposed on children from diarrheal diseases. Recent clinical trial results show that Napo's lead drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2009-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry